Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall

Sep 21 2016

• By Alexandra Shimmings

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells — • Source: Shutterstock, Kateryna Kon

Related Content

Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start

Mar 14 2013

Adventrx becomes Mast Therapeutics to sail away from troubled chemo drug programs

Mar 03 2013

Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188

Jan 22 2015

Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness

Sep 15 2016

Related Companies

Mast Therapeutics, Inc.

GSK plc

Daiichi Sankyo Co., Ltd.

Eli Lilly and Company

Pfizer Inc.

GlycoMimetics, Inc.

Additional Topics

Clinical Trials Research & Development Blood & Coagulation Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window